Abstract
As a class of proteins that play crucial roles in physiological and pathological processes within the human body, G protein-coupled receptors (GPCRs) have emerged as prominent targets for drug development. However, there is still ample room for improvement and replacement of currently developed drugs due to their inherent toxicity and associated side effects. In recent years, the attention has shifted towards antibody-based therapeutics targeting GPCRs, owing to their exceptional specificity and low plasma clearance rate. This review provides an overview of the fundamental preparation process and existing challenges encountered in developing GPCR antibody drugs, along with an introduction to several strategies employed in their formulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
